Clinical Trial Update: Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial at MD Anderson is evaluating a quadruplet regimen of cladribine, idarubicin, cytarabine, and quizartinib for newly diagnosed, relapse…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Biphenotypic Leukemia
• High-risk Myelodysplastic Syndrome

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Cladribine (cladribine)
• Idarubicin (idarubicin)
• Quizartinib (Quizartinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Acute Myeloid Leukemia, Blasts 20 Percent or More of Bone Marrow Nucleated Cells | Phase 1, Phase 2 | Status: RECRUITING